It's the first new type of painkiller in 20 years. And it's just a few weeks away from being here in local pharmacies.
Vertex Pharmaceuticals (NASDAQ:VRTX) received an upgrade from Canaccord Genuity after the cystic fibrosis drugmaker exceeded consensus revenue estimates but missed on earnings with its Q4 2024 ...